Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379375 | 0.98 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL6951792 | 0.84 | TSHR (0.51) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11859597 | 0.82 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL28002074 | 0.82 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL27788695 | 0.81 | LMNA (0.46) | — | |
| SCHEMBL3650820 | 0.81 | LMNA (0.46) | — | |
| SCHEMBL27779720 | 0.80 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL29214387 | 0.80 | LMNA (0.45) | SLC6A3SLC6A2 | |
| SCHEMBL4206472 | 0.80 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL9678056 | 0.80 | GABRA1 (0.41) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115475153-A | Glycopyrronium bromide liquid medicine for inhalation and application thereof | 南京华盖制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-7253182-B2 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | SOFOTEC GMBH & CO. KG (DE) | 2007-08-07 | — | — | US | disclosed |
| US-20030220400-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | Noe, Christian | 2003-11-27 | — | — | US | disclosed |
| US-6613795-B2 | Respiratory system disorders; muscle relaxants | Noe, Christian (DE) | 2003-09-02 | — | — | US | disclosed |
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CHRISTIAN NOE AND ERNST MUTSCHLER | 2002-11-21 | — | — | US | disclosed |
| US-6307060-B1 | ANTISPASMODIC AGENTS | Noe, Christian | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | SLC6A3 3980/4885SLC6A2 3854/4885SLC6A4 3768/4885 |
| US-20030220400-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | SLC6A3 3980/4885SLC6A2 3854/4885SLC6A4 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.